Cell Therapy in China: Production and Quality Inspection
Clinical Trials & Advanced Therapies
When a cell therapy product is prepared from a patient's own cells, quality is not an abstract property of the hospital — it depends on the apheresis, the manufacturing run, the release testing and the chain of identity that links all three. Patients are entitled to ask how that chain is controlled.
The production chain
- Collection — apheresis at the hospital, with cell count and viability recorded
- Transport — controlled temperature and documented handover to the manufacturing site
- Manufacturing — expansion or genetic modification under a defined batch record
- Release testing — sterility, identity, purity, potency and, where relevant, vector copy number
- Return and infusion — verified identity match before the product leaves the laboratory
Quality questions worth asking
- Is the manufacturing site accredited, and has it produced this product before?
- What are the release criteria, and what happens if a batch fails them?
- How many days between apheresis and infusion, and what is the fallback if the product does not expand?
- Who pays for a repeat apheresis or a second manufacturing run?
Why the chain of identity matters most
Autologous products carry an inherent risk: the wrong product reaching the wrong patient. Serious programmes use independent identity verification at collection, at release and at the bedside, with two people checking. If a centre cannot describe that process clearly, that is information in itself.
Documentation to keep
Ask for the batch record summary, release test results and infusion record. These documents are what a physician at home will need if you develop a delayed complication, and they are difficult to obtain retrospectively.
Next step: if you are comparing centres for a CAR-T or other autologous therapy, send us the proposals and we will point out which quality questions each one has left unanswered.
